Evolving strategies for second- and third-line treatments in multiple myeloma

Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the evolving strategies for second and third-line treatments in multiple myeloma, highlighting the role of lenalidomide resistance and the increasing use of anti-CD38 monoclonal antibodies. He notes the promising potential of bispecific antibodies in later lines of therapy, with hopes for their early application in the future. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.